https://www.massbio.org/news/member-news/calluna-pharma-completes-enrollment-in-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis-ipf/
Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary...
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data...